(Q45856165)

17 December 2017

title

Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer (English)

1 reference

17 December 2017

0 references

Gustavo Ayala

1

1 reference

17 December 2017

Takefumi Satoh

2

1 reference

17 December 2017

Rile Li

3

1 reference

17 December 2017

Moshe Shalev

4

1 reference

17 December 2017

Yehoshua Gdor

5

1 reference

17 December 2017

Estuardo Aguilar-Cordova

6

1 reference

17 December 2017

Anna Frolov

7

1 reference

17 December 2017

Thomas M Wheeler

8

1 reference

17 December 2017

Brian J Miles

9

1 reference

17 December 2017

Kate Rauen

10

1 reference

17 December 2017

Bin S Teh

11

1 reference

17 December 2017

E Brian Butler

12

1 reference

17 December 2017

Timothy C Thompson

13

1 reference

17 December 2017

Dov Kadmon

14

1 reference

17 December 2017

publication date

15 February 2006

1 reference

17 December 2017

published in

Molecular Therapy

1 reference

17 December 2017

volume

13

1 reference

17 December 2017

page(s)

716-728

1 reference

17 December 2017

issue

4

1 reference

17 December 2017

National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission on Cancer

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.022

In situ gene therapy for prostate cancer: immunomodulatory approaches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.022

Gene therapy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.022

Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.022

Cytopathic effect of in situ gene therapy in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.022

Human prostate carcinoma cells as targets for herpes simplex virus thymidine kinase-mediated suicide gene therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.022

Adenovirus-mediated suicide-gene therapy using the herpes simplex virus thymidine kinase gene in cell and animal models of human prostate cancer: changes in tumour cell proliferative activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.022

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.022

Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.022

Osteocalcin-directed gene therapy for prostate-cancer bone metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.022

Thymidine kinase, thymidylate synthase, and endothelial cell growth under hyperoxia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.022

The use of suicide gene systems in vascular cells in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.022

Reduction of restenosis after angioplasty in an atheromatous rabbit model by suicide gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.022

Effect of adenoviral-mediated thymidine kinase transduction and ganciclovir therapy on tumor-associated endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.022

In vivo surgical resection plus adjuvant gene therapy in the treatment of mammary and prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.022

Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.022

Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.022

Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.022

Prospects for herpes-simplex-virus thymidine-kinase and cytokine gene transduction as immunomodulatory gene therapy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.022

Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.022

Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.022

Prodrug activation gene therapy and external beam irradiation in the treatment of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.022

10.1016/J.YMTHE.2005.11.022

7 January 2021

Identifiers

DOI

1 reference

17 December 2017

PubMed ID

16480930

1 reference

17 December 2017